Intracranial dissemination of a macroprolactinoma

J. Assies; N. P. Verhoeff; D. A. Bosch; L. J. Hofland

doi:https://doi.org/10.1111/j.1365-2265.1993.tb00351.x

Intracranial dissemination of a macroprolactinoma

J. Assies, N. P. Verhoeff, D. A. Bosch, L. J. Hofland

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Scopus)

Abstract

A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502

Original language	English
Pages (from-to)	539-546
Journal	Clinical endocrinology
Volume	38
Issue number	5
DOIs	https://doi.org/10.1111/j.1365-2265.1993.tb00351.x
Publication status	Published - 1993

Access to Document

https://doi.org/10.1111/j.1365-2265.1993.tb00351.x

Cite this

@article{b2ec4cade20b43488e66c7d08944010f,

title = "Intracranial dissemination of a macroprolactinoma",

abstract = "A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502",

author = "J. Assies and Verhoeff, {N. P.} and Bosch, {D. A.} and Hofland, {L. J.}",

year = "1993",

doi = "https://doi.org/10.1111/j.1365-2265.1993.tb00351.x",

language = "English",

volume = "38",

pages = "539--546",

journal = "Clinical endocrinology",

issn = "0300-0664",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Intracranial dissemination of a macroprolactinoma

AU - Assies, J.

AU - Verhoeff, N. P.

AU - Bosch, D. A.

AU - Hofland, L. J.

PY - 1993

Y1 - 1993

N2 - A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502

AB - A patient with a macroprolactinoma and extrasellar extension was treated by incomplete transfrontal surgery, external irradiation and additional bromocriptine (Br) treatment. After 4 years, partial bromocriptine resistance developed (a rare occurrence) together with the appearance of intracranial metastases. 123I-Iodobenzamide was helpful in evaluating the dopamine D2 receptor status of the metastatic tumour both in vivo using single-photon emission computed tomography (SPECT) and in vitro. Prolactin release by the cultured metastatic tumour cells was more potently inhibited by CV 205-502 than by bromocriptine. The patient, treated by surgery, irradiation and CV 205-502, developed a ptosis of the left eye and a transient psychiatric delusional state, the latter probably an effect of the dopamine agonist. As the right frontal metastasis was markedly positive on SPECT with 111In-SMS, somatostatin treatment was added to the CV 205-502

U2 - https://doi.org/10.1111/j.1365-2265.1993.tb00351.x

DO - https://doi.org/10.1111/j.1365-2265.1993.tb00351.x

M3 - Article

C2 - 8101148

SN - 0300-0664

VL - 38

SP - 539

EP - 546

JO - Clinical endocrinology

JF - Clinical endocrinology

IS - 5

ER -